Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring.
Molinos-Quintana Á, Alonso-Saladrigues A, Herrero B, Caballero-Velázquez T, Galán-Gómez V, Panesso M, Torrebadell M, Delgado-Serrano J, Pérez de Soto C, Faura A, González-Martínez B, Castillo-Robleda A, Diaz-de-Heredia C, Pérez-Martínez A, Pérez-Hurtado JM, Rives S, Pérez-Simón JA. Molinos-Quintana Á, et al. Among authors: caballero velazquez t. Front Immunol. 2024 Jan 16;14:1280580. doi: 10.3389/fimmu.2023.1280580. eCollection 2023. Front Immunol. 2024. PMID: 38292483 Free PMC article.
[Classification of chronic graft-versus-host disease].
Caballero Velázquez T, Pérez Simón JA. Caballero Velázquez T, et al. Methods Find Exp Clin Pharmacol. 2010 Dec;32 Suppl A:65-8. Methods Find Exp Clin Pharmacol. 2010. PMID: 21381291 Spanish.
The novel combination of sirolimus and bortezomib prevents graft-versus-host disease but maintains the graft-versus-leukemia effect after allogeneic transplantation.
Caballero-Velázquez T, Sánchez-Abarca LI, Gutierrez-Cosio S, Blanco B, Calderon C, Herrero C, Carrancio S, Serrano C, del Cañizo C, San Miguel JF, Pérez-Simón JA. Caballero-Velázquez T, et al. Haematologica. 2012 Sep;97(9):1329-37. doi: 10.3324/haematol.2011.058677. Epub 2012 Apr 24. Haematologica. 2012. PMID: 22532520 Free PMC article.
Uptake and delivery of antigens by mesenchymal stromal cells.
Sánchez-Abarca LI, Alvarez-Laderas I, Díez Campelo M, Caballero-Velázquez T, Herrero C, Muntión S, Calderón C, García-Guerrero E, Sánchez-Guijo F, Del Cañizo C, San Miguel J, Pérez-Simón JA. Sánchez-Abarca LI, et al. Cytotherapy. 2013 Jun;15(6):673-8. doi: 10.1016/j.jcyt.2013.01.216. Epub 2013 Mar 21. Cytotherapy. 2013. PMID: 23522868
Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients.
Caballero-Velázquez T, López-Corral L, Encinas C, Castilla-Llorente C, Martino R, Rosiñol L, Sampol A, Caballero D, Serrano D, Heras I, San Miguel J, Pérez-Simón JA. Caballero-Velázquez T, et al. Br J Haematol. 2013 Aug;162(4):474-82. doi: 10.1111/bjh.12410. Epub 2013 Jun 15. Br J Haematol. 2013. PMID: 23772672 Free article. Clinical Trial.
Sequential third-party mesenchymal stromal cell therapy for refractory acute graft-versus-host disease.
Sánchez-Guijo F, Caballero-Velázquez T, López-Villar O, Redondo A, Parody R, Martínez C, Olavarría E, Andreu E, Prósper F, Díez-Campelo M, Regidor C, Villaron E, López-Corral L, Caballero D, Cañizo MC, Pérez-Simon JA. Sánchez-Guijo F, et al. Biol Blood Marrow Transplant. 2014 Oct;20(10):1580-5. doi: 10.1016/j.bbmt.2014.06.015. Epub 2014 Jun 19. Biol Blood Marrow Transplant. 2014. PMID: 24952358 Free article. Clinical Trial.
65 results